David E. I. Pyott David E. I. Pyott, former Chairman and CEO of Allergan, Inc., was appointed to Tarsus Pharmaceuticals' Board of Directors. IRVINE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Tarsus ...

David Pyott isn’t interested in becoming a chief executive again—“17 years as a public CEO was enough, and I do not wish to jump into another company, where in my view four years is the minimum time ...

David Pyott expected 2014 to be a year of hunting for deals. The tables were turned when Allergan Inc., the Irvine-based drugmaker he’s led for the past 16 years, became the hunted. “Normally, very ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Sienna Biopharmaceuticals announced in a ...

Talk about golden parachutes: Allergan’s Chief Executive Officer, David Pyott, could collect as much as $126 million after the company he’s run for the past 17 years is acquired by Ireland-based ...

Dr. David Pyott, Director, Pliant Therapeutics Inc. Dr. Pyott joins the Pliant Board of Directors with more than 30 years of executive leadership and management experience within the global ...

Some stories end with happy-ever-after. Some endings are bitter sweet. When David Pyott became CEO of Allergan, the maker of Botox, he never imagined that his leading role would end as the latter.

The directors of a company tend to have a unique inside view into the business, so when directors make major buys, investors are wise to take notice. Presumably the only reason a director of a company ...

Some stories end with happy-ever-after. Some endings are bitter sweet. When David Pyott became CEO of Allergan, the maker of Botox, he never imagined that his leading role would end as the latter.